Inside the Arab World’s Psychedelic Therapy Revival Now

Sep 19

6 min read

This article summarizes verified reporting from DoubleBlind Magazine’s August 7, 2026 feature, “Inside the Arab World’s Psychedelic Revival.” All facts and figures below are attributed to DoubleBlind’s original piece, available here: Inside the Arab World’s Psychedelic Revival.

Clinical interest in psychedelic-assisted therapy is rising across the South-West Asian and North African (SWANA) region. DoubleBlind Mag documents a pragmatic mix of models: Lebanon’s ketamine care that operates within existing law, the United Arab Emirates’ state-led exploration, Jordan’s evidence-first professional debate, and Egypt’s rediscovery of its own mid‑century LSD research lineage.

Across SWANA, mental health need is high while services are limited. Public surveys in many Arab countries suggest that close to 30% report depression, and one UAE study found 57.2% of residents met criteria for at least one diagnosable disorder (DoubleBlind). Lebanon saw a 42% year-over-year rise in suicides in July 2022, amid compounding crises (DoubleBlind).

Scientific Evidence and Research Findings

An empty infusion bay at Beirut’s American University of Beirut Medical Center illustrates hospital-based ketamine research and care. — AUBMC has provided ketamine therapy for treatment-resistant depression and suicidal ideation since 2017.

Lebanon demonstrates an active, measurable model. Since 2017, clinics at the American University of Beirut Medical Center (AUBMC) and St. George Hospital have provided ketamine therapy for treatment‑resistant depression and suicidal ideation. According to DoubleBlind’s reporting, psychiatrist Dr. Farid Talih at AUBMC has observed up to a 90% reduction in suicidal ideation, with depression response rates ranging from 30% to nearly 90%.

Clinically, ketamine’s pathway in Lebanon is a regulatory workaround: the medicine is classified as an anesthetic‑dissociative, enabling off‑label psychiatric use under existing law (DoubleBlind). Programs are explicitly organized around recognized diagnoses, not framed as war‑trauma clinics, even if daily life stressors may contribute to patient demand.

Jordan offers a window into clinician sentiment. A 2025 survey in the Journal of Psychoactive Drugs, led by Jordanian researchers and summarized by DoubleBlind, polled nearly 2,000 physicians and medical students: 50% opposed psychedelic therapy, 34.1% cautious, and 15.5% supportive. Professional seniority did not change attitudes. Advocates in Jordan are focusing on presenting peer‑reviewed efficacy data at medical conferences and in universities.

In the UAE, policy frameworks are emerging alongside caution. DoubleBlind notes the National Strategy for Wellbeing 2031 and the 2024 Federal Mental Health Law as foundations for future research, while clinics such as The Valens Clinic in Dubai already offer esketamine for depression within current rules. However, December 2025 drug law amendments tightened penalties on controlled substances, creating uncertainty that has slowed some physicians’ research plans.

Medical Applications and Patient Benefits

DoubleBlind’s reporting centers the clearest real‑world patient benefits in Lebanon’s ketamine programs. These clinics address treatment‑resistant depression and suicidal ideation—conditions frequently underserved across the region—within established hospital settings. Reported outcomes include clinically meaningful response rates and marked reductions in suicidal thinking.

While the UAE is not broadly treating patients with classic psychedelics, esketamine access shows how a “psychedelic‑adjacent” therapy can integrate into care. State‑led initiatives signal interest in positioning the country for medical innovation and tourism, but practical patient benefits will depend on whether research exceptions and clinical protocols are formally authorized (DoubleBlind).

Egypt’s contribution, per DoubleBlind, is historical and infrastructural. The Behman Hospital and the Greek Hospital in Cairo were part of international LSD research in the 1950s–60s. Today, Egypt has 61 licensed mental health facilities and a 2009 Mental Health Act that can frame future research, yet workforce constraints are severe—0.68 psychiatrists per 100,000 people and fewer than 120 clinical psychologists for 100+ million residents—limiting patient access now.

Safety Considerations and Side Effects

DoubleBlind’s article emphasizes structural and legal safety more than pharmacologic side effects. Across many SWANA jurisdictions, possession carries heavy penalties, and trafficking is a capital offense in several countries. Regulatory ambiguity—such as the UAE’s 2025 penalty tightening—can chill research and clinical development, even when wellbeing strategies signal interest in innovation.

Access equity is another key safety dimension. DoubleBlind warns that psychedelic care may become available primarily to wealthy Gulf residents and medical tourists unless deliberate policies address cost, training, and equitable distribution. In Lebanon, session costs are several hundred dollars—already out of reach for many amid economic collapse.

Cultural and religious fit also matter. DoubleBlind notes that some Muslim participants in Western trials have struggled with therapy music, language, and integration practices not grounded in their worldview. UK‑based faith leader Sughra Ahmed—featured in NPR reporting referenced by DoubleBlind—now hosts monthly gatherings to process experiences through an Islamic lens, illustrating a culturally attuned integration model.

Importantly, DoubleBlind does not enumerate drug‑specific adverse events. Instead, it documents how clinical programs have been diagnosis‑driven, embedded in hospitals, and mindful of legal and cultural context. Readers considering any intervention should consult licensed clinicians and follow local laws.

Religious and Cultural Context

A softly lit circle of cushions and tea vessels evokes culturally grounded discussion of psychedelic experiences. — Faith leaders and community organizers are exploring ways to process psychedelic experiences through Islamic cultural frameworks.

DoubleBlind reports an active theological dialogue reframing psychedelics within regional history rather than as foreign imports. Haya Al‑Hejailan, founder of the Arab Psychedelic Society, points to indigenous pharmacopeia: acacia species in the Middle East contain DMT, and Syrian rue has MAOI properties. Sufi traditions of ecstatic practice also echo contemporary accounts of ego‑dissolution.

As summarized by DoubleBlind, NPR’s reporting captured two influential perspectives. Yasir Qadhi, chair of the Fiqh Council of North America, noted that psychedelics do not map neatly onto alcohol’s category in Islamic law, while stopping short of endorsing therapeutic use. Chaplain Kamal Abu‑Shamsieh framed psychedelics as a medical question evaluated by patient and evidence. The Fiqh Council’s permissive ruling on medical cannabis in serious conditions serves as a precedent in these debates.

Lebanon

• Active hospital‑based ketamine therapy since 2017 at AUBMC and St. George Hospital.• Outcomes include up to 90% reduction in suicidal ideation; 30–90% depression response rates.• Access limited by cost and instability; programs are diagnosis‑focused rather than war‑trauma clinics.

United Arab Emirates

• National Strategy for Wellbeing 2031 and Federal Mental Health Law (2024) lay groundwork.• SEHA Mental Health Services hosted high‑profile conferences in 2023–2024.• The Valens Clinic offers esketamine; 2025 drug‑law amendments tightened penalties, tempering momentum.

Jordan

• 2025 survey of ~2,000 doctors/students: 50% opposed, 34.1% cautious, 15.5% supportive.• Advocates focus on peer‑reviewed data and professional education to shift opinion.

Egypt

• Historical LSD research at Cairo’s Behman Hospital and the Greek Hospital in the 1950s–60s.• Today: 61 licensed mental health facilities; Mental Health Act (2009) frames research ethics.• Workforce constraints limit near‑term scale‑up despite cultural leadership potential.

What this means for DC, Maryland and Virginia

For DMV clinicians and policymakers, DoubleBlind’s reporting outlines three workable levers: evidence‑first education (Jordan), legal pathways that exist already (Lebanon’s off‑label ketamine), and structured, state‑led planning (UAE). Thoughtful combinations of these approaches can inform local conversations on emerging therapies—always within current law and medical standards.

For patients and communities in Washington DC, Maryland, and Virginia, the SWANA experience underscores two practical needs: access equity and cultural integration. Programs that center diagnosis, clinician training, and faith‑aware support systems are more likely to serve diverse communities safely. The medical‑cannabis precedent referenced by DoubleBlind in faith debates shows how religious guidance can evolve when evidence and patient need are clear.

Note: This article does not describe DMV law or availability. Always verify current regulations and talk with licensed healthcare professionals before pursuing any therapy.

Is psychedelic therapy currently available in the SWANA region?

DoubleBlind confirms that Lebanon actively treats patients with ketamine at AUBMC and St. George Hospital. Elsewhere, programs are preparatory: the UAE is building policy frameworks, Jordan is debating evidence, and Egypt is reconnecting with historical research foundations.

Which conditions are being treated?

In Lebanon, ketamine programs focus on treatment‑resistant depression and suicidal ideation as clinical diagnoses, not as war‑trauma programs (DoubleBlind).

Are classic psychedelics (like psilocybin or LSD) in use?

DoubleBlind documents historical LSD research in Egypt and present‑day ketamine programs in Lebanon. The article does not report active, legal clinical use of classic psychedelics for patients elsewhere in SWANA at this time.

What do religious scholars say?

Per DoubleBlind’s summary of NPR reporting, scholars like Yasir Qadhi note psychedelics do not align cleanly with alcohol in Islamic law, and Kamal Abu‑Shamsieh emphasizes patient‑ and evidence‑based evaluation. The Fiqh Council’s permissive stance on medical cannabis for serious conditions offers a relevant precedent.

What are the main barriers to access?

DoubleBlind highlights cost, limited clinician training, regulatory uncertainty, and legal penalties in many countries. Workforce shortages—especially in Egypt—further constrain scale‑up.

Is this primarily about war trauma?

DoubleBlind’s answer is “mostly no, not yet.” Lebanon’s working model is organized around depression and suicidality. The infrastructure to run large war‑trauma psychedelic programs is not yet in place across SWANA.

Virginia Maryland and Washington DC Weed Delivery
Exotic Cannabis Online Dispensary

(202) 952- 6195

(202) 701- 7458